Key result
Low molecular weight heparin reduced the frequency of deep vein thrombosis compared to placebo in elderly medical in-patients.
Why the study?
Does low molecular weight heparin prevent deep vein thrombosis in elderly medical in-patients over 65 years?
RCT (n=270)
Double-blind
randomized
Does low molecular weight heparin prevent deep vein thrombosis in elderly medical in-patients over 65 years?
Low molecular weight heparin (60 mg daily) significantly reduces the occurrence of deep vein thrombosis in elderly medical in-patients compared to placebo.
Answers are grounded in this paper and cite their sources.
LMWH 60 mg daily should be considered for DVT prevention in elderly medical in-patients; confirms benefit versus placebo in this RCT.
Two hundred and seventy patients over 65 years were included in a placebo-controlled randomized double-blind trial to determine whether a small dose of a low molecular weight (LMW) heparin prevents the occurrence of deep vein leg thrombosis (DVT) diagnosed by 125I fibrinogen scanning. LMW heparin (60 mg daily) significantly reduced the frequency of DVT from 9 to 3 percent (p = 0.03). Adverse drug reactions did not differ significantly between the 2 groups, except for the injection site hematomas that were more frequent in the LMW heparin group. In conclusion, LMW heparin appears of value in preventing the occurrence of DVT in an unselected elderly in-patient population.
No takes yet. Share an insight, caveat, or question.
Dahan et al. (2009) conducted an RCT in Deep vein thrombosis prevention (n=270). Low molecular weight (LMW) heparin vs. Placebo was evaluated on Occurrence of deep vein leg thrombosis (DVT) diagnosed by 125I fibrinogen scanning (p=0.03). Low molecular weight heparin reduced the frequency of deep vein thrombosis compared to placebo in elderly medical in-patients.
Synapse has enriched 10 related papers. Consider them for comparative context: